The Law Office of Abe Shainberg Launches an Investigation into the Possible Breaches of Fiduciary Duty by the Board of Cypres...

The Law Office of Abe Shainberg is investigating the Board of Directors of Cypress Bioscience (NASDAQ:CYPB) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to sell the Company to Ramius V&O Acquisition LLC, an affiliate of Ramius LLC and affiliates of Royalty Pharma. Under the terms of the transaction, Cypress shareholders will receive $6.50 per share in cash for a total transaction value of approximately $255 million.

The investigation concerns whether the Cypress Board of Directors breached their fiduciary duties to Cypress stockholders by failing to adequately shop the Company before entering into this transaction and whether the buyers are underpaying for Cypress shares. At least one analyst set a price target for Cypress stock at $7.00.

If you own common stock in Cypress and wish to obtain additional information, please contact Abe Shainberg, Esq. either via email at [e-mail] or by telephone at [phone], or visit http://www.ashainberglaw.com/cypressbio-cypb.html.

Mr. Shainberg has expertise in prosecuting investor securities litigation, is a certified and registered arbitrator and mediator involving financial matters, and represents investors in various matters nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.